TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26044442

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target systolic blood pressure <140 mmHg)
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Guideline-based blood pressure management (target systolic blood pressure <180 mmHg)
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: All grading scales (original intracerebral hemorrhage, modified intracerebral hemorrhage, intracerebral hemorrhage grading scale)
Number of subjects: 2839
Study: 24229558

Group type: EXPERIMENTAL
Intervention: Educational video method
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Role-playing method
Number of subjects: 144
Study: 21441882

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 19797280

Group type: EXPERIMENTAL
Intervention: Dietary intervention, self-monitoring of blood glucose, and insulin therapy if necessary
Number of subjects: 958

Group type: COMPARATOR
Intervention: Usual prenatal care (control group)
Number of subjects: 958
Study: 16672093

Group type: COMPARATOR
Intervention: No remifentanil infusion (n = 21)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 1 ng mL(‐1) remifentanil (n = 24)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 3 ng mL(‐1) remifentanil (n = 22)
Number of subjects: 67
Study: 15596872

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 114

Group type: COMPARATOR
Intervention: Distal protection
Number of subjects: 114
Study: 10635266

Group type: EXPERIMENTAL
Intervention: Manual interdental cleaning
Number of subjects: 35

Group type: COMPARATOR
Intervention: Interclean Interdental Plaque Remover
Number of subjects: 35
Study: 7502115

Group type: EXPERIMENTAL
Intervention: MiniMed implantable insulin pump (MIP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36
Study: 2309999

Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.3 mg kg‐1)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Meperidine (1 mg kg‐1)
Number of subjects: 170
Study: 7011964

Group type: EXPERIMENTAL
Intervention: Propranolol + Hydrochlorothiazide (P+H)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Oxprenolol + Hydrochlorothiazide (O+H)
Number of subjects: 260
Study: 30507561

Group type: EXPERIMENTAL
Intervention: Squatting exercise in addition to a traditional physical therapy program
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Squatting with hip adduction exercise in addition to a traditional physical therapy program
Number of subjects: 30
Study: 28729003

Group type: EXPERIMENTAL
Intervention: Activity Promotion System (APs) with a wearable device and web-based feedback system
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual care with traditional health education
Number of subjects: 53
Study: 23688197

Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Passive Stretching (PASS)
Number of subjects: 18
Study: 22955576

Group type: EXPERIMENTAL
Intervention: Class II elastics (A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Class III elastics (B)
Number of subjects: 32
Study: 20127794

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for nightmares
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 18315451

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 500 to 1500 mg b.i.d.
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 16222404

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition for a mean duration of 15.8 days (range 8-23)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study: 12177649

Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol therapy (200 mg/day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Aspirin plus ticlopidine hydrochloride therapy (200 mg/day)
Number of subjects: 130
Study: 10414568

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 30
Study: 7589028

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) infusion at doses of 0.015, 0.25, 1.0, and 2.0 micrograms.kg‐1.min‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (isotonic saline) infusion
Number of subjects: 12
Study: 2250227

Group type: EXPERIMENTAL
Intervention: LongoVital (LV)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 7282730

Group type: EXPERIMENTAL
Intervention: Erosive disease identified in patients with sickle cell anemia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Loss of definition of the cortical margin in the superior aspect of the calcaneus
Number of subjects: 100
Study: 30905851

Group type: EXPERIMENTAL
Intervention: Emergency transvaginal cervico‐isthmic cerclage
Number of subjects: 3
Study: 28202004

Group type: EXPERIMENTAL
Intervention: LY2603618/gemcitabine
Number of subjects: 99

Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 99
Study: 26486789

Group type: EXPERIMENTAL
Intervention: FCR (fludarabine, cyclophosphamide, and rituximab)
Number of subjects: 817

Group type: COMPARATOR
Intervention: FC (fludarabine and cyclophosphamide)
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: FCR
Number of subjects: 817

Group type: COMPARATOR
Intervention: FC
Number of subjects: 817
Study: 24552318

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus radiotherapy and temozolomide
Number of subjects: 921

Group type: COMPARATOR
Intervention: Placebo plus radiotherapy and temozolomide
Number of subjects: 921
Study: 21909634

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19251770

Group type: EXPERIMENTAL
Intervention: Moderated support group (password-protected access to health portal)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Unmoderated support group (no password-protected access to health portal)
Number of subjects: 108
Study: 17309966

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clamp-and-tie technique
Number of subjects: 200
Study: 16763491

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (HIV informational program)
Number of subjects: 140
Study: 15252191

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10758467

Group type: EXPERIMENTAL
Intervention: Oral etilefrine 15 mg (30 drops), 60 min before the subarachnoid block
Number of subjects: 40

Group type: COMPARATOR
Intervention: No etilefrine (control group)
Number of subjects: 40
Study: 8649652

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia (euglycaemic hyperinsulinaemic clamp technique)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia (euglycaemic hyperinsulinaemic clamp technique) + Angiotensin II (0.1 ng/kg per min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hyperinsulinaemia (euglycaemic hyperinsulinaemic clamp technique) in lean control group
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hyperinsulinaemia (euglycaemic hyperinsulinaemic clamp technique) in weight-matched control group
Number of subjects: 14

Group type: COMPARATOR
Intervention: Angiotensin II
Number of subjects: 14
Study: 1635123

Group type: EXPERIMENTAL
Intervention: 3 adjuvant cycles of methotrexate, vinblastine and cisplatin plus doxorubicin (M‐VAC) or epirubicin (M‐VEC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 49
Study: 6731015

Group type: EXPERIMENTAL
Intervention: E-Z-CAT (barium sulphate suspension)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gastrografin (water-soluble iodinated contrast medium)
Number of subjects: 100
Study: 30761846

Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal herniorrhaphy (TEP)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Open Lichtenstein herniorrhaphy (OLR)
Number of subjects: 302
Study: 28614399

Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS over the left DLPFC for 7 consecutive days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 25
Study: 27038611

Group type: EXPERIMENTAL
Intervention: Dader method for pharmaceutical care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Health/dietary counseling and risk reduction (Control)
Number of subjects: 120
Study: 25261605

Group type: EXPERIMENTAL
Intervention: Titrated oxygen therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 18
Study: 21842241

Group type: EXPERIMENTAL
Intervention: Combination PPI plus rebamipide
Number of subjects: 170

Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI)
Number of subjects: 170
Study: 19874926

Group type: EXPERIMENTAL
Intervention: Sci-B-Vac vaccine (3 doses, 0-1-6 month scheme)
Number of subjects: 28
Study: 17257476

Group type: EXPERIMENTAL
Intervention: Tramadol/Acetaminophen (APAP) 37.5 mg tramadol/325 mg APAP, up to 1-2 tablets four times daily for 66 days
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Tramadol/Acetaminophen (APAP)
Number of subjects: 313
Study: 15279347

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill
Number of subjects: 230

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 230
Study: 11262515

Group type: EXPERIMENTAL
Intervention: Inositol (18 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9853542

Group type: EXPERIMENTAL
Intervention: Beta-carotene (betaC) supplementation (30 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene (betaC) supplementation with UV exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UV exposure
Number of subjects: 0
Study: 7986136

Group type: EXPERIMENTAL
Intervention: Laparoscopic staging with laparoscopic ultrasonography
Number of subjects: 50

Group type: COMPARATOR
Intervention: No laparoscopic assessment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasonography
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 50
Study: 2646779

Group type: EXPERIMENTAL
Intervention: CsA-P
Number of subjects: 224

Group type: COMPARATOR
Intervention: AZA-P-ALG
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Triple/Quadruple therapy (AZA-P-CsA or AZA-P-CsA-ALG)
Number of subjects: 224
Study: 31081924

Group type: EXPERIMENTAL
Intervention: verum CBM/verum tDCS
Number of subjects: 79

Group type: COMPARATOR
Intervention: verum CBM/sham tDCS
Number of subjects: 79

Group type: COMPARATOR
Intervention: sham CBM/verum tDCS
Number of subjects: 79

Group type: COMPARATOR
Intervention: sham CBM/sham tDCS
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combined CBM and tDCS
Number of subjects: 79
Study: 28462519

Group type: EXPERIMENTAL
Intervention: Ivabradine (7.5 mg b.i.d.)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 179
Study: 26355170

Group type: EXPERIMENTAL
Intervention: Short implants (5.0 to 8.5 mm)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Augmented group with longer implants (at least 11.5 mm)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Augmented group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Short implants and augmented group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 23801842

Group type: EXPERIMENTAL
Intervention: Combined LAM and ADV therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: LAM alone (monotherapy)
Number of subjects: 140
Study: 20878425

Group type: EXPERIMENTAL
Intervention: 4 g/day mesalazine (two divided doses)
Number of subjects: 123

Group type: COMPARATOR
Intervention: 2.25 g/day mesalazine (three divided doses)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 4 g/day mesalazine
Number of subjects: 123

Group type: COMPARATOR
Intervention: 2.25 g/day mesalazine
Number of subjects: 123
Study: 20026933

Group type: EXPERIMENTAL
Intervention: Cyclic pressure-relief protocol using an individually adjusted automated seat in wheelchairs.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard wheelchair seating (control group).
Number of subjects: 44
Study: 17675076

Group type: EXPERIMENTAL
Intervention: Atrial-based pacing
Number of subjects: 2568

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 2568

Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacing (irrespective of pacing mode)
Number of subjects: 2568
Study: 15543905

Group type: EXPERIMENTAL
Intervention: Fixed prosthodontics
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Removable dentures
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Complete dentures
Number of subjects: 107

Group type: COMPARATOR
Intervention: Removable/Complete dentures
Number of subjects: 107

Group type: COMPARATOR
Intervention: General population
Number of subjects: 107
Study: 12180581

Group type: EXPERIMENTAL
Intervention: Clonidine 1 microg/kg added to local anaesthetic mixture (2% lignocaine and hyaluronidase)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group received 7 ml of a mixture of 2% lignocaine and hyaluronidase with 1 ml normal saline
Number of subjects: 24
Study: 10638158

Group type: EXPERIMENTAL
Intervention: BAR (mechanical device)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GIA stapling device
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Manual suture with interrupted stitches double layer (vicryl)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 7741773

Group type: EXPERIMENTAL
Intervention: Caroverine 40 mg intravenously
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caroverine 80 mg intravenously
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caroverine 40 mg orally
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caroverine 80 mg orally
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caroverine (all doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caroverine (lowest oral dose)
Number of subjects: 15
Study: 1970370

Group type: EXPERIMENTAL
Intervention: Oral cyclosporin (initial dose 2.5 mg/kg, mean stabilisation dose 3.8 mg/kg)
Number of subjects: 144
Study: 6989432

Group type: EXPERIMENTAL
Intervention: High-dose aspirin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intermittent low-pressure pneumatic compression device (IPCD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30256671

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target <120 mmHg)
Number of subjects: 4298

Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target <140 mmHg)
Number of subjects: 4298
Study: 27379963

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Traditional strength training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 24633694

Group type: EXPERIMENTAL
Intervention: Co‐occurring internalizing and externalizing comorbidities
Number of subjects: 392

Group type: COMPARATOR
Intervention: Internalizing comorbidity alone
Number of subjects: 392

Group type: COMPARATOR
Intervention: Externalizing comorbidity alone
Number of subjects: 392

Group type: COMPARATOR
Intervention: No comorbidities
Number of subjects: 392
Study: 24472614

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 68
Study: 22625222

Group type: EXPERIMENTAL
Intervention: Krachtvoer programme
Number of subjects: 1875

Group type: COMPARATOR
Intervention: Regular nutrition lessons (control)
Number of subjects: 1875
Study: 19604181

Group type: EXPERIMENTAL
Intervention: Music intervention (n = 92)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no music, n = 88)
Number of subjects: 180
Study: 18087004

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone plus azathioprine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone plus mycophenolate mofetil
Number of subjects: 73
Study: 15497024

Group type: EXPERIMENTAL
Intervention: Pycnogenol (100 mg per capsule, 2 capsules taken 2-3 hours before flight, 2 capsules 6 hours later, 1 capsule the next day)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo (comparable to Pycnogenol, same intervals)
Number of subjects: 198
Study: 11585312

Group type: EXPERIMENTAL
Intervention: Scleral buckling
Number of subjects: 400

Group type: COMPARATOR
Intervention: Primary vitrectomy
Number of subjects: 400
Study: 9008444

Group type: EXPERIMENTAL
Intervention: American Heart Association Step 1 diet plus lovastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: American Heart Association Step 1 diet plus placebo
Number of subjects: 40
Study: 8342398

Group type: EXPERIMENTAL
Intervention: Oestrogen-progesterone therapy (uncontrolled trial)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.050 mg ethinyloestradiol and 1 mg norethisterone (double-blind randomized placebo-controlled trial)
Number of subjects: 20
Study: 3015184

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (40 Gy in split-course)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 145
Study: 31985067

Group type: EXPERIMENTAL
Intervention: myFAMI intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 31856576

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 392
Study: 27915159

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 49
Study: 26525615

Group type: EXPERIMENTAL
Intervention: Intravenous cytoflavin (2 ml per 1 kg of body weight per day for five days)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Basic therapy (control group)
Number of subjects: 89
Study: 23088837

Group type: EXPERIMENTAL
Intervention: Ambu(®) aScope™ 2
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional fibrescope
Number of subjects: 50
Study: 22051427

Group type: EXPERIMENTAL
Intervention: Blood pressure measurements recorded in electronic medical records (EMRs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood pressure measurements taken at research study visit
Number of subjects: 0
Study: 19407274

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mixed treatment group
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-antipsychotic group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study: 17589948

Group type: EXPERIMENTAL
Intervention: OAC7 (7-day triple therapy: omeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: OAC14 (14-day triple therapy: omeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: OAC7 (7-day triple therapy)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: OAC14 (14-day triple therapy)
Number of subjects: 131
Study: 15107145

Group type: EXPERIMENTAL
Intervention: 0.39 mg THC/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 0.47 mg THC/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 7.5 mg THC/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 14.8 mg THC/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 0.39 to 14.8 mg THC/day
Number of subjects: 7
Study: 11569764

Group type: EXPERIMENTAL
Intervention: Inter-generational discount rates for long delays (30-900 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inter-generational discount rates for saving lives, improving health, and financial benefits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inter-generational discounting of life-saving programs
Number of subjects: 0
Study: 9645714

Group type: EXPERIMENTAL
Intervention: Preenucleation radiation treatment
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Uveal melanoma
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Increased pigmentation
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Increased necrosis
Number of subjects: 1527
Study: 7961018

Group type: EXPERIMENTAL
Intervention: Continuous radiotherapy (CG)
Number of subjects: 1446

Group type: COMPARATOR
Intervention: Split-course radiotherapy (SG)
Number of subjects: 1446
Study: 3314526

Group type: EXPERIMENTAL
Intervention: Topical prednisolone phosphate 1%
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2-deoxycytidine 100 microM
Number of subjects: 11
Study: 2265802

Group type: EXPERIMENTAL
Intervention: Spermatozoa capacitated in hyperosmotic medium of 315 mosm/kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Spermatozoa capacitated in hyperosmotic medium of 345 mosm/kg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Spermatozoa incubated in medium of 285 mosm/kg
Number of subjects: 54
Study: 989400

Group type: EXPERIMENTAL
Intervention: 5 mg of diazepam
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: BAY g 5653 (three doses)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 180
Study: 31311721

Group type: EXPERIMENTAL
Intervention: NAC + calmangafodipir (2 μmol/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NAC + calmangafodipir (5 μmol/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NAC + calmangafodipir (10 μmol/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: NAC alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NAC + calmangafodipir
Number of subjects: 24